Stock Track | Cellebrite Soars 6.43% Pre-market on Strong Q2 Results and Positive Outlook

Stock Track
Aug 14, 2025

Cellebrite (CLBT) shares surged 6.43% in pre-market trading on Thursday following the release of its impressive second-quarter 2025 financial results and optimistic future guidance. The digital intelligence solutions provider reported significant growth across key metrics, outperforming analyst expectations in several areas.

For Q2 2025, Cellebrite posted revenue of $113.276 million, surpassing the IBES estimate of $112.2 million. The company's subscription revenue saw a robust 21% year-over-year increase to $103.0 million, while Annual Recurring Revenue (ARR) grew by 21% to $418.9 million. Despite the net income of $19.476 million falling short of the IBES estimate of $25.4 million, investors seemed to focus on the company's strong top-line performance and future prospects.

Adding to the positive sentiment, Cellebrite provided an encouraging outlook for Q3 and full-year 2025. The company expects Q3 ARR to be between $435 million and $445 million, representing a 17% to 20% annual growth rate. For the full year, Cellebrite projects ARR between $460 million and $475 million, with revenue ranging from $465 million to $475 million. The company also announced the appointment of Thomas E. Hogan as CEO, who expressed confidence in Cellebrite's continued growth and support for its customers in law enforcement, defense, and intelligence sectors.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10